179
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma

, , , , , , , , & show all
Pages 357-367 | Received 12 Oct 2022, Accepted 16 Feb 2023, Published online: 02 Mar 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.